Drug Trial Radar · NCT05822752
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
130
Actual
Start
Sep 21, 2023
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), lenvatinib, or sorafenib. Approximately 120 adult participants will be enrolled in the study across 60 sites worldwide. In arm 1 (control), participants will receive the investigator's choice: lenvatinib as an oral capsule or sorafenib as an oral tablet, once daily. In arm 2, participants will receive intravenously (IV) infused livmoniplimab (dose A) in combination with IV infused budigalimab, every 3 weeks. In arm 3, participants will receive intravenously (IV) infused livmoniplimab (dose B) in combination with IV infused budigalimab, every 3 weeks. The estimated duration of the study is up to 2 years There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Conditions
- Hepatocellular Carcinoma
Interventions
BudigalimabDrug
Intravenous (IV) Infusion
LivmoniplimabDrug
Intravenous (IV) Infusion
LenvatinibDrug
Oral: Capsule
SorafenibDrug
Oral: Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response (BOR) per InvestigatorTime frame: Through Study Completion, Up to Approximately 27 Months
Locations
59 sites in 7 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313
Prescott Valley, Arizona
Highlands Oncology Group, PA /ID# 253158
Springdale, Arkansas
University of California, Los Angeles /ID# 253292
Los Angeles, California
UC Irvine /ID# 252707
Orange, California
California Pacific Medical Center - San Francisco - Webster Street /ID# 253291
San Francisco, California
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163
Denver, Colorado
AdventHealth Orlando /ID# 252865
Orlando, Florida
The University of Chicago Medical Center /ID# 252870
Chicago, Illinois
Hematology/Oncology Clinic /ID# 253851
Baton Rouge, Louisiana
Dana-Farber Cancer Institute /ID# 252696
Boston, Massachusetts
Henry Ford Hospital /ID# 253342
Detroit, Michigan
Washington University-School of Medicine /ID# 252698
St Louis, Missouri
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708
New York, New York
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252705
New York, New York
Messino Cancer Center - Asheville /ID# 253888
Asheville, North Carolina
University of North Carolina /ID# 252739
Chapel Hill, North Carolina
Lifespan Cancer Institute at Rhode Island Hospital /ID# 252699
Providence, Rhode Island
Duplicate_Texas Oncology - Medical City Dallas /ID# 254164
Dallas, Texas
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 252770
Dallas, Texas
Texas Oncology - Northeast Texas /ID# 254184
Tyler, Texas
AP-HP - Hopital Paul-Brousse /ID# 253646
Villejuif, France
Centre Hospitalier Universitaire de Bordeaux /ID# 252749
Pessac, Gironde, France
CHU Montpellier - Hopital Saint Eloi /ID# 252760
Montpellier, Herault, France
Hopital Beaujon /ID# 252758
Clichy, Île-de-France Region, France
CHU Grenoble - Hopital Michallon /ID# 252755
La Tronche, Isere, France
CHRU Lille - Hopital Claude Huriez /ID# 252748
Lille, Nord, France
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 253247
Bologna, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 253142
Palermo, Italy
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 253141
Roma, Italy
Azienda Ospedaliero Universitaria Careggi /ID# 254444
Florence, Firenze, Italy
IRCCS Ospedale San Raffaele /ID# 252910
Milan, Milano, Italy
P.O. Ospedale del Mare /ID# 253140
Naples, Napoli, Italy
Chiba University Hospital /ID# 255190
Chiba, Chiba, Japan
National Cancer Center Hospital East /ID# 253419
Kashiwa-shi, Chiba, Japan
Kanazawa University Hospital /ID# 254861
Kanazawa, Ishikawa-ken, Japan
Yokohama City University Medical Center /ID# 255790
Yokohama, Kanagawa, Japan
Kindai University Hospital /ID# 255106
Osakasayama-shi, Osaka, Japan
CHA Bundang Medical Center /ID# 253054
Seongnam, Gyeonggido, South Korea
Seoul National University Bundang Hospital /ID# 253412
Seongnam-si, Gyeonggido, South Korea
Chonnam National University Hwasun Hospital /ID# 253133
Hwasun-gun, Jeonranamdo, South Korea
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.